image credit: Freepik

Biogen, ViGeneron Enter Gene Therapy Collaboration

January 5, 2021

ViGeneron GmbH, a gene therapy company, has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases.

The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

“Gene therapy has become a clinical reality. At ViGeneron, we are dedicated to developing innovative gene therapies to treat diseases with high unmet medical need. This collaboration exemplifies our strategy to develop in-house programs for selected retinal targets, while maximizing our proprietary technology platforms with additional collaboration programs for other targets in ophthalmology and further indications,” said Dr. Caroline Man Xu, co-founder and CEO of ViGeneron.

Read More on Contract Pharma